title: Hepatitis B virus reactivation in a chronic myeloid leukemia patient treated with imatinib mesylate.
abstract: Imatinib mesylate is a molecular targeted agent for treating chronic myeloid leukemia (CML) and gastrointestinal stromal tumor. Although imatinib mesylate is not regarded as an immunosuppressive agent, few studies have also shown that it may impair immune response. In this report, we present a case of transient hepatitis B virus (HBV) reactivation during imatinib mesylate treatment for CML.
authors.affiliation: Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
authors.forename: Ya-Dan
authors.initials: YD
authors.lastname: Wang
authors.forename: Guo-Hui
authors.initials: GH
authors.lastname: Cui
authors.forename: Mian
authors.initials: M
authors.lastname: Li
authors.forename: Bhuveshwarnath
authors.initials: B
authors.lastname: Gowrea
authors.forename: Jia
authors.initials: J
authors.lastname: Xia
authors.forename: Yu
authors.initials: Y
authors.lastname: Hu
mesh_terms: D000328:Adult; D001549:Benzamides; D006515:Hepatitis B virus / Q000472:pathogenicity*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000821:virology*; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D014779:Virus Replication / Q000187:drug effects
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate